A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout

PHASE3CompletedINTERVENTIONAL

Enrollment

779

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

December 13, 2023

Study Completion Date

August 23, 2024

Conditions

Gout

Interventions

DRUG

SHR4640

SHR4640 Dose 1 ,tablets, QD

DRUG

Allopurinol

Allopurinol 300mg, tablets, QD

Trial Locations (1)

RenJi Hospital, Shanghai JiaoTong University School Of Medicine, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY